Metabolic alterations in sepsis and vasoactive drug-related metabolic effects.
The main clinical characteristics of sepsis and septic shock are derangements of cardiocirculatory and respiratory function. Additionally, profound alterations in metabolic pathways occur leading to hypermetabolism, enhanced energy expenditure, and insulin resistance. The clinical hallmarks are hyperglycemia, hyperlactatemia, and enhanced protein catabolism. These metabolic alterations are even more pronounced during sepsis as a result of cytokine release and subsequent induction of inflammatory pathways. Increased oxygen demands from mitochondrial oxygen utilization and oxygen consumption related to oxygen radical formation may contribute to hypermetabolism. In addition, mitochondrial dysfunction with impaired cellular respiration may be present. Mainstay therapeutic interventions for hemodynamic stabilization are adequate volume resuscitation and vasoactive agents, which, however, have additional impact on metabolic activity. Therefore, beyond hemodynamic effects, specific drug-related metabolic alterations need to be considered for optimal treatment during sepsis. This review gives an overview of the typical metabolic alterations during sepsis and septic shock and highlights the impact of vasoactive therapy on metabolism.
Träger
Karl
K
Klinik für Anästhesiologie, Universitätsklinikum Ulm, Germany. karl.traeger@medizin.uni-ulm.de
DeBacker
Daniel
D
Radermacher
Peter
P
D000322:Adrenergic Agonists / Q000627:therapeutic use*; D002395:Catecholamines / Q000627:therapeutic use*; D016638:Critical Illness; D004734:Energy Metabolism / Q000187:drug effects*; D011464:Epoprostenol / Q000627:therapeutic use; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007773:Lactates / Q000378:metabolism; D008928:Mitochondria / Q000502:physiology; D018805:Sepsis / Q000378:metabolism* / Q000503:physiopathology; D014667:Vasopressins / Q000627:therapeutic use
D000322:Adrenergic Agonists; D002395:Catecholamines; D007773:Lactates; D014667:Vasopressins; D011464:Epoprostenol; D005947:Glucose